Episode 36: Novo Nordisk

Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness.

In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landmark merger, global expansion, and steady leadership in diabetes care. We explore how the company mastered insulin manufacturing, pioneered drug delivery systems, and quietly built one of the most disciplined scientific cultures in pharma.

This is a story about patience, focus, and how decades of unglamorous excellence can suddenly change the world.

🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday!

https://linktr.ee/maneadkhin

#NovoNordisk #Biotech #Pharma #GLP1 #Ozempic #Wegovy #Diabetes #Obesity #Healthcare #LifeSciences #Biopharma #SciencePodcast #BusinessOfBiotech #MedicalInnovation #PetriDishPerspectives

Transcript

Hello and welcome to Petri Dish Perspectives, the podcast where we geek out about science and the companies shaping the future of healthcare. I’m your host, Manead, and I’m a PhD scientist by training, biotech storyteller by choice. With every new episode released on Thursday, my goal is to deliver digestible pieces of information on healthcare companies under 30 mins. 

Today, we’re going to talk about a global diabetes and obesity market leader, Novo Nordisk, who, by the way, is also a direct competitor of Eli Lilly. 

Why listen to this episode? Because we’re gonna talk all about the diabetes/obesity market, the science behind blockbuster drugs like Ozempic/Wegovy, and the impact of GLP-1s on healthcare.

Quick disclaimer, I give full credit to the original articles cited in the references in the transcript!

Grab a coffee or tea, settle in, and let’s jump in!

Segment 1: Origins in Insulin and a Divided Beginning

Novo Nordisk’s story begins in the early 1920s, at a moment when diabetes was still widely fatal. Following the discovery of insulin in Canada, access to the drug became a matter of national urgency. In Denmark, this urgency sparked two parallel efforts that would define the company’s future.

August Krogh, a Danish physiologist and Nobel laureate, recognized insulin’s significance almost immediately. After traveling to North America and securing rights to manufacture insulin in Scandinavia, his wife Marie Krogh, herself a physician, helped establish Nordisk Insulinlaboratorium in 1923. Around the same time, Harald and Thorvald Pedersen, former colleagues, founded Novo Terapeutisk Laboratorium after a professional split.

For decades, Novo and Nordisk operated as rivals. They competed on insulin purity, yield, stability, and delivery methods. This rivalry, while personal and at times bitter, created an environment of relentless scientific improvement. Denmark became a global center of excellence in diabetes care, not because of one company, but because of two pushing each other forward.

This dual-company era shaped Novo Nordisk’s DNA. From the beginning, success was measured not in speed or hype, but in reliability, manufacturing rigor, and trust from physicians and patients.

Segment 2: Consolidation, Globalization, and the Road to Public Markets

By the 1980s, the logic of competition gave way to the necessity of scale. Diabetes was becoming a global epidemic, and insulin manufacturing required enormous capital investment, regulatory sophistication, and global distribution.

In 1989, Novo and Nordisk merged to form Novo Nordisk. The merger unified decades of expertise and positioned the company to compete globally, particularly against emerging US and European pharmaceutical giants.

Novo Nordisk had already been publicly listed in Denmark, but the newly merged company began to think more deliberately about global capital markets. Over the 1990s and early 2000s, Novo Nordisk expanded its presence with listings that increased international investor access, including American Depositary Receipts in the US. These listings were not growth-at-all-costs events. Instead, they reflected Novo’s steady philosophy: raise capital to fund manufacturing, research, and long-term disease leadership.

Unlike many biotechs, Novo did not go public on the promise of a single breakthrough. It entered global markets with revenue, products, and a clear therapeutic identity. Investors were buying a system, not a story.

Novo Nordisk (NVO) didn't have a single "first-time IPO" in recent history; rather, its constituent parts merged in 1989, and its IT spin-off NNIT had its own successful debut in 2015, but the main company originally went public in 1981, becoming a global giant in diabetes and obesity treatments, listing on US exchanges like NYSE as NVO after its Danish roots. In January 1986, NVO was at $0.14 per stock. 

Segment 3: Mastering Diabetes Through Incremental Excellence

For much of its modern history, Novo Nordisk focused obsessively on insulin and diabetes care. The company refined insulin analogs to improve predictability and reduce hypoglycemia risk. It invested heavily in delivery systems, pioneering insulin pens that replaced syringes and transformed daily treatment.

This was not flashy innovation, but it was transformative. Novo understood that chronic disease success depends on adherence, usability, and trust. Its insulin pens became a competitive moat, embedding Novo into patients’ daily lives.

By the early 2000s, Novo Nordisk was the undisputed leader in diabetes care. It had built unmatched manufacturing expertise, deep regulatory relationships, and a culture that valued decades-long thinking. This foundation would soon enable its most important scientific leap.

Segment 4: GLP-1 Biology and the Reinvention of Metabolic Disease

The discovery of GLP-1 biology marked Novo Nordisk’s second founding moment. Academic researchers had shown that GLP-1, a gut-derived hormone, regulated insulin secretion, appetite, and gastric emptying. Novo recognized early that this biology could redefine metabolic disease treatment.

Years of molecular engineering followed. GLP-1 degrades rapidly in the body, and stabilizing it required deep peptide chemistry expertise. Novo’s persistence paid off with liraglutide, followed by semaglutide, which demonstrated superior efficacy, once-weekly dosing, and strong cardiovascular outcomes.

This was not just a diabetes breakthrough. Clinical trials revealed consistent, meaningful weight loss. Novo made a decisive strategic move: obesity would be treated as a chronic disease, not a lifestyle failure.

This shift required courage. Obesity drugs had a history of failure and controversy. Novo leaned on data, long-term trials, and regulatory discipline, ultimately leading to Wegovy’s approval.

Segment 5: Ozempic, Wegovy, and the Cultural Moment

Ozempic and Wegovy catapulted Novo Nordisk into public consciousness. The drugs delivered weight loss results that were visible, scalable, and unprecedented for pharmacotherapy. Media coverage exploded. Celebrities referenced them. Social platforms amplified personal transformations.

What made this moment different was not just celebrity use, but legitimacy. These were FDA-approved drugs backed by rigorous trials, not supplements or fads. The convergence of science, social media, and unmet medical need created a global demand shock.

Novo faced manufacturing constraints, supply shortages, and ethical debates around access. Diabetes patients worried about availability. Policymakers questioned pricing. Novo responded by expanding manufacturing aggressively while emphasizing appropriate medical use.

This period tested Novo’s values. Its response reinforced its identity as a long-term healthcare company rather than a trend-driven brand.

Segment 6: People Who Made Their Mark

Novo Nordisk’s success is inseparable from its people. August and Marie Krogh laid the scientific and ethical foundation. Harald and Thorvald Pedersen embodied entrepreneurial persistence.

In the modern era, Lars Rebien Sørensen, CEO from 2000 to 2016, reshaped Novo into a global, purpose-driven organization, emphasizing sustainability, access, and long-term value. His successor, Lars Fruergaard Jørgensen, guided the company through the GLP-1 explosion with operational discipline and strategic restraint.

Behind the scenes, generations of peptide chemists, endocrinologists, manufacturing engineers, and regulatory leaders built capabilities competitors struggled to replicate. Novo’s scientists did not chase novelty; they chased reliability at scale.

Segment 7: Competition, Pressure, and Strategic Discipline

Novo Nordisk now operates in one of the most competitive markets in pharmaceutical history. Eli Lilly’s tirzepatide raised efficacy benchmarks and intensified the race for next-generation incretin therapies.

Novo has responded by investing in oral GLP-1s, combination therapies, and next-wave metabolic biology. The company continues to prioritize cardiovascular outcomes, durability, and tolerability rather than headline weight loss alone.

This competition underscores a broader truth: Novo’s greatest asset is not a single drug, but a platform built over decades.

Segment 8: What’s Next for Novo Nordisk

Today, Novo Nordisk is one of the largest and most influential pharmaceutical companies in the world. It employs over 64,000 people globally, with operations in more than 80 countries and production facilities across Denmark, the United States, France, China, and Brazil.

The company is investing tens of billions of dollars to expand manufacturing capacity, particularly in injectable and peptide-based therapies. Its pipeline extends beyond diabetes and obesity into cardiovascular disease, chronic kidney disease, liver disease, and potentially neurodegenerative disorders.

Novo Nordisk is no longer just treating disease. It is shaping how chronic metabolic conditions are defined, regulated, and managed worldwide.

By the time the episode was recorded, Novo Nordisk’s stock stands at $50.88 and the market cap is at approximately $173B. 

Segment 9: Lessons from Novo Nordisk

Novo Nordisk teaches that enduring success comes from focus, patience, and systems thinking. It shows that public markets can reward discipline, that culture compounds over decades, and that science paired with manufacturing excellence can reshape global health.

Novo did not invent insulin. It perfected everything around it. And when the world finally demanded metabolic solutions at scale, Novo Nordisk was ready.

Outro

With that, that is a wrap on Novo Nordisk episode. I hope that you got a look into what the diabetes industry looked like and how different it would’ve been without Novo Nordisk and of course, popular culture with Ozempic simply can’t be ignored. 

This has been Petri Dish Perspectives. I’m Manead. Thanks for listening.

References

1. www.wikipedia.org
2. www.nature.com 
3. https://endpoints.news/ 
4. www.finance.yahoo.com  

© 2025 Petri Dish Perspectives LLC. All rights reserved.